Drugs that contain Budesonide
1. Entocort Ec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5643602 | PADAGIS US | Oral composition for the treatment of inflammatory bowel disease |
Jul, 2014
(9 years ago) | |
|
US5643602 (Pediatric) | PADAGIS US | Oral composition for the treatment of inflammatory bowel disease |
Jan, 2015
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2019 |
| M(M-178) | Apr 29, 2019 |
Market Authorisation Date: 02 October, 2001
Treatment: Treatment of mild to moderate active chrohn's disease involving the ileum and/or the ascending colon and the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum a...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ENTOCORT EC family patents
2. Ortikos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
| US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(12 years from now) | |
Market Authorisation Date: 13 June, 2019
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ORTIKOS family patents
3. Pulmicort Flexhaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6287540 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US6027714 | ASTRAZENECA | Formulation for inhalation |
Jan, 2018
(6 years ago) | |
| US7143764 | ASTRAZENECA | Inhalation device |
Mar, 2018
(6 years ago) | |
| US6142145 | ASTRAZENECA | Inhalation device |
May, 2018
(5 years ago) | |
Market Authorisation Date: 12 July, 2006
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma
Dosage: POWDER, METERED;INHALATION
PULMICORT FLEXHALER family patents
4. Pulmicort Respules patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7524834 | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
Nov, 2018
(5 years ago) | |
| US6598603 | ASTRAZENECA | Method for treating respiratory diseases |
Dec, 2018
(5 years ago) | |
| US6899099 | ASTRAZENECA | Method for treating a respiratory disease |
Dec, 2018
(5 years ago) | |
|
US7524834 (Pediatric) | ASTRAZENECA | Sterile powders, formulations, and methods for producing the same |
May, 2019
(4 years ago) | |
|
US6598603 (Pediatric) | ASTRAZENECA | Method for treating respiratory diseases |
Jun, 2019
(4 years ago) | |
|
US6899099 (Pediatric) | ASTRAZENECA | Method for treating a respiratory disease |
Jun, 2019
(4 years ago) | |
Market Authorisation Date: 08 August, 2000
Treatment: Treatment of asthma (maintenance and prophylactic therapy); Once daily treatment of asthma with nebulized budesonide
Dosage: SUSPENSION;INHALATION
PULMICORT RESPULES family patents
5. Rhinocort patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6986904 | ASTRAZENECA PHARMS | Formulation |
Apr, 2017
(6 years ago) | |
| US6686346 | ASTRAZENECA PHARMS | Formulation |
Apr, 2017
(6 years ago) | |
| US6291445 | ASTRAZENECA PHARMS | Low dose budesonide formulations and uses thereof |
Apr, 2017
(6 years ago) | |
|
US6686346 (Pediatric) | ASTRAZENECA PHARMS | Formulation |
Oct, 2017
(6 years ago) | |
|
US6986904 (Pediatric) | ASTRAZENECA PHARMS | Formulation |
Oct, 2017
(6 years ago) | |
|
US6291445 (Pediatric) | ASTRAZENECA PHARMS | Low dose budesonide formulations and uses thereof |
Oct, 2017
(6 years ago) | |
Market Authorisation Date: 01 October, 1999
Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms
Dosage: SPRAY, METERED;NASAL
RHINOCORT family patents
6. Tarpeyo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
| New Product(NP) | Dec 15, 2024 |
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TARPEYO family patents
7. Uceris patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5914122 | SALIX | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams |
Dec, 2015
(8 years ago) | |
| US9320716 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US7410651 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| USRE43799 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US9532954 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10064878 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10105374 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US10143698 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US8784888 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US8293273 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Jun, 2020
(3 years ago) | |
| US7431943 | SALIX | Controlled release and taste masking oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
| US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2017 |
Market Authorisation Date: 07 October, 2014
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: AEROSOL, FOAM;RECTAL; TABLET, EXTENDED RELEASE;ORAL
UCERIS family patents